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Accumulating evidence suggests that
latent infection with Toxoplasma gondii
is associated with a variety of neuropsy-
chiatric and behavioural conditions.
Many of the conditions associated with
T. gondii can be explained by emerging
understanding of the parasite’s neuro-
tropic activity.
The public health burden of latent infec-
tion may far outweigh that caused byGregory Milne ,1,2,* Joanne P. Webster,1,2 and Martin Walker1,2
Traditionally, the protozoan parasite Toxoplasma gondii has been thought of as
relevant to public health primarily within the context of congenital toxoplasmosis
or postnatally acquired disease in immunocompromised patients. However,
latent T. gondii infection has been increasingly associated with a wide variety
of neuropsychiatric disorders and, more recently, causal frameworks for these
epidemiological associations have been proposed. We present assimilated
evidence on the associationsbetweenT. gondii and various humanneuropsychiatric
disorders and outline how these may be explained within a unifying causal frame-
work. We argue that the occult effects of latent T. gondii infection likely outweigh
the recognised overt morbidity caused by toxoplasmosis, substantially raising the
public health importance of this parasite.acute and congenital toxoplasmosis.
More powerful epidemiological studies,
in conjunctionwith furthermechanistic in-
vestigations, are needed to strengthen
the evidence base for T. gondii as a
causal agent of a range of neuropsy-
chiatric and behavioural disorders.
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Evidence of exposure to the apicomplexan protozoan parasite Toxoplasma gondii, which is
capable of infecting all warm-blooded animals, is found in approximately 30% of the world’s
human population [1]. However, seroprevalence shows marked global variability: for example,
in highly endemic regions, such as parts of Africa, seroprevalence can reach almost 90% in
certain demographic groups, whereas in some European populations it can reach 60% [2].
Felines are the only known definitive host (see Glossary) for the parasite, shedding in their
faeces up to millions of oocysts per day, which sporulate and become infective in the environ-
ment [3]. While in domestic cats, oocyst shedding occurs for only 1–3 weeks after initial infection,
in wild feline species shedding may potentially continue intermittently for life [3]. Ingestion of these
sporulated oocysts, which contaminate crops, soil, and water sources [4,5], or consumption of
bradyzoites from raw or undercooked meat comprise the two major horizontal routes of
transmission. Indeed, these parasite stages are responsible for a substantial burden of postnatally
acquired infections, causing both sporadic outbreaks of acute, symptomatic disease in immuno-
competent adults [6] and severe toxoplasmosis in immunocompromised individuals including
HIV/AIDS patients (following reactivation of bradyzoites into disseminating tachyzoites) [7].
In humans, congenital toxoplasmosis is acknowledged as a significant public health problem
[8,9]. Vertical transmission of T. gondii from mother to foetus occurs most frequently following
a primary maternal infection during pregnancy (although other means of vertical transmission
are possible, including infection with an atypical genotype overriding acquired immunity from a
prior nonatypical exposure [10]). While the likelihood of maternofoetal transmission is highest in
the third trimester, the severity of congenital disease has the inverse relationship with gestational
age, such that first-trimester infections generally result in the most severe clinical symptoms in
neonates, including spontaneous abortion or stillbirth [8]. While overall approximately 75% of
congenital cases are subclinical, congenital infection, amongst those surviving infants, can none-
theless result in various craniocerebral, ocular, and/or cognitive abnormalities in early or later life
(e.g., chorioretinitis, intracranial calcifications, and learning difficulties [8]).
Latent T. gondii infection, following postnatally acquired (acute) infection, has historically been
considered benign or even asymptomatic in immunocompetent individuals [1,11,12]. Yet aTrends in Parasitology, Month 2020, Vol. xx, No. xx https://doi.org/10.1016/j.pt.2020.08.005 1
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Glossary
Bradyzoite: the slowly dividing, sessile
parasite stage that is found within tissue
cysts in various body regions, including
skeletal and cardiac muscles, the eyes,
and central nervous system (with a
preference for neuronal and glial cells).
Bradyzoites are associated with latent
infection and cannot be cleared by any
current antiparasitic drugs.
Chorioretinitis: inflammation of the
choroid layer of the eye, superior to the
retina and inferior to the sclera. Scarring,
particularly in the macular region of the
eye, and necrotic lesions are consistent
features.
Definitive host: the organism(s) which
supports the sexually reproducing stage
of the parasite.
Effect size: the magnitude of an
association between an exposure
(e.g., infection) and an outcome
(e.g., neuropsychiatric disease). Effect
sizes are frequently expressed as RRs
(or relative risks) or ORs, depending on
the study design.
Intermediate host: the organism(s)
which harbour the asexual parasite stage
and which allow for transmission to the
definitive host. In the case of T. gondii,
examples include rodents and birds
(domestic cat prey) and potentially
wildebeest and zebra (large wild cat
prey).
Intracranial calcifications: deposits
of calcium within the brain, often
associated with infection with TORCH
agents (toxoplasmosis,
Cytomegalovirus, and Herpes simplex
virus). Infants with these lesions are
suspected to be at increased risk of
severe neuropsychiatric sequelae.
Latent T. gondii infection: the phase
ofT. gondii infection inwhich the parasite
remains in tissue cysts as bradyzoites.
Odds ratio (OR): an effect size metric
which is most frequently calculated from
case–control studies to quantify the
magnitude of association between an
exposure and a disease.
Oocyst: an environmentally resistant
parasite stage which contains the sexual
stage sporozoites that are produced in
intestinal cells of the felid definite hosts.
Depending on environmental conditions
(e.g., temperature and humidity),
oocysts can survive for many years.
Population attributable fraction
(PAF): the burden of a particular
outcome (e.g., a neuropsychiatric
disorder) attributable to an exposure
(e.g., infection with T. gondii).
Trends in Parasitologyburgeoning number of epidemiological studies suggest that the parasite can be associated with a
number of long-term behavioural effects in hosts, including humans. In rodent intermediate
hosts, T. gondii can cause a range of behavioural alterations, including altered activity levels,
decreased neophobic behaviour and a ‘fatal feline attraction’ to cat urine, thereby increasing the
efficiency of transmission to the definitive host [13]. Similar by-product (nonadaptive, or residual
manipulative [14]) behavioural effects, from the subtle (e.g., changes in personality traits) to the
severe (e.g., increased risk of schizophrenia), have also been identified in T. gondii-infected humans
[15,16]. Here, we review the increasing number of human disorders that have been linked to
T. gondii infection and argue that these occult effects raise the public health burden of this chronic
parasitic infection far beyond that recognised by the overt burden of acute disease.
How Does Toxoplasma Cause Neuropsychiatric Disease?
The first studies describing potential associations between latent T. gondii infection and human
neuropsychiatric disorders, in this case schizophrenia, were published in the 1950s [16] (even
before the parasite's life cycle was completely understood [17]). After a lull in interest, the 21st
century has seen a proliferation of studies – followed by a flurry of meta-analyses – on associa-
tions between T. gondii infection and a wide variety of cognitive and neuropsychiatric disorders,
including Alzheimer’s disease [18], bipolar disorder [19,20], epilepsy [21], and obsessive–
compulsive disorder (OCD) [19] (Figure 1). Whilst these studies and meta-analyses have
demonstrated consistent support for the link with schizophrenia [19,22,23], the strength of
evidence for other disorders is variable (Figure 2).
The association between T. gondii and neuropsychiatric conditions could partly be explained by
the influence of the parasite on the expression of several neurotransmitters. Dopamine dysregu-
lation, which has received the most research attention, results partly from the parasite’s ability to
synthesise tyrosine hydrolase (an enzyme involved in dopamine biosynthesis) [24]. T. gondii also
alters the expression of a range of other neurotransmitters, including γ-aminobutyric acid (GABA),
glutamate, serotonin, and norepinephrine [25]. These effects might be mediated by the
encystment of bradyzoites in neural – and most often microglial or neuronal – cells, thereby
causing considerable alterations, both in host neurobiochemistry and in the expression of specific
receptors/transporters [24,25]. For example, it has been shown, in chronically infected mice,
that T. gondii decreases the expression of the glutamate transporter GLT-1, resulting in a twofold
increase in extracellular glutamate concentrations [26].
In humans, dysregulation of neurotransmitter expression is critically involved in many behavioural
and neuropsychiatric conditions, including bipolar disorder, depression, drug addiction, OCD,
schizophrenia, and suicide [25]. As examples, changes in dopamine-mediated neurotransmis-
sion have been proposed to be involved in the pathophysiology of both addictive and obsessive
behaviours [27,28], and serotonin is thought to play a central role in the aetiology of mood disor-
ders [29]. T. gondii is auxotrophic for tryptophan – the precursor to serotonin – and low plasma
tryptophan concentrations have been associated with cases of severe depression [30,31].
A differing hypothesis is that changes in the endocrine system, particularly testosterone expres-
sion, may drive behavioural changes observed in T. gondii-infected hosts. The evidence to
support this comes from in vivo studies showing that infected male rodents have higher concen-
trations of testosterone and reduced innate aversion to the odour of cat urine compared with
uninfected controls (with castration prior to infection rescuing the aberrant behavioural
phenotype) [32,33]. Furthermore, castrated male mice given exogenous testosterone display a
reduced aversion to cat odour, which corresponds to changes in regulatory gene methylation
patterns in the extended medial amygdala [33]. Hence, it is plausible that both neurotransmitter2 Trends in Parasitology, Month 2020, Vol. xx, No. xx
Risk ratio (RR): an effect size metric
typically calculated from cohort studies
to quantify the risk of developing a
disease associated with a particular
exposure.
Secondary host: the organism(s) which
harbour the asexual parasite stage. Unlike
intermediate hosts, secondary hosts do
not necessarily support transmission to
the definitive host. In the case of T. gondii,
examples include non-prey animal
associates of the cat, for example, cow,
sheep, and human.
Tachyzoite: the rapidly dividing
parasite stage associated with acute
infection. Tachyzoites disseminate
infection throughout the body prior to
the establishment of a latent infection
and may reactivate from bradyzoite
cysts in immunocompromised
individuals.
Toxoplasmic encephalitis:
inflammation of the brain which results
most often from
immunocompromisation and
subsequent reactivation of T. gondii
bradyzoites in tissue cysts into
tachyzoites, which invade and replicate
in new cells.
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Figure 1. Publication History of Datasets from Meta-Analyses Associating Toxoplasma gondii with
Neuropsychiatric and Behavioural Disorders. Published datasets (N = 202) collected across 39 countries and cited
in 15 systematic reviews, assessing the relationship between T. gondii infection and neuropsychiatric disorders, grouped
by: (A) specific neuropsychiatric and behavioural disorders (arrows indicate years in which systematic reviews were
published); (B) World Health Organization (WHO) global region in which the study was conducted (for all studied disorders
combined).
Trends in Parasitologyand endocrine dysregulation have roles to play in the behavioural changes associated with
T. gondii infection.
A notable exception to the neuromodulation-based (or endocrine-based) mechanistic explanation
is the association of T. gondii infection with epilepsy. Development of epilepsy is likely primarily
determined by the pattern and extent of cyst presence and/or rupture in the brain and the subse-
quent formation of scar tissue [34]. In agreement with a nonspecific infectious aetiology of some
cases of epilepsy, a case–control study conducted in sub-Saharan Africa found the prevalence
of active convulsive epilepsy to be higher among individuals seropositive for T. gondii, although
also among those seropositive for a range of other parasitic infections, including Onchocerca
volvulus and Toxocara canis (with numerous other studies reporting associations between epilepsy
and the aetiological agent of neurocysticercosis, Taenia solium [35]) [36]. Interestingly, theTrends in Parasitology, Month 2020, Vol. xx, No. xx 3
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Figure 2. Toxoplasma gondii and Associated Human Behavioural and Neuropsychiatric Disorders. The
association of T. gondii IgG seroprevalence in humans with various disorders compared with IgG seroprevalence in
healthy control subjects. Each odds ratio (OR) shows the strength of association stated in a published systematic review
and meta-analysis [18–21,23,46,47,71–77]. For some disorders more than one meta-analysis was published, and hence
multiple ORs are presented in these cases. Note that the ORs for cryptogenic and convulsive epilepsy are calculated using
subgroup analysis of one of the epilepsy metanalyses [21]. Studies were found using PubMed and Google Scholar with
terms “Toxoplasma gondii OR toxoplasmosis” AND [name of disorder]. Abbreviation: CI, confidence interval.
Trends in Parasitologycombined effects of certain coinfecting agents was more than additive [36], findings which are in
agreement with the increasingly recognised notion that many human neuropsychiatric disorders
may have a multi-infectious agent causation (Box 1) [37,38].
Another potential key and interrelated mechanistic factor in the propensity of T. gondii to cause
behavioural alterations is the host's immune response. Following infection, immune cells in the
small intestine, including innate lymphoid cells, are stimulated to produce a range of cytokines
and transcription factors. Notable amongst these defences are cytokines, including interferon-
gamma (IFN-γ), interleukin-12 (IL-12), and tumour necrosis factor-alpha (TNF-α), and
chemokines, including CCL2 and CXCL2, which are produced by activated immune cells such
as macrophages and dendritic cells, prompting further immune cell activation and anti-T. gondii
gene expression (for a review see [39]). While this immune responsemediates the effective control
of acute infection, it also contributes to the maintenance of parasite latency and, potentially, to the
development or aggravation of neurological sequelae. Studies using rodent models have
observed excessive levels of proinflammatory cytokines, including TNF-α and IL-6, in the
serum of mothers of offspring who later developed psychotic-like symptoms [40]. Interestingly,
TNF-α and IL-6 have both been shown to promote bradyzoite formation in murine and cell culture
models [41], and in humans, perinatal exposure to TNF-α and IL-8 has been linked to develop-
ment of schizophrenia in offspring [42].
It is therefore likely that a number of mechanistic pathways, including endocrine and neurotrans-
mitter dysregulation and the proinflammatory immune response to infection (including, potentially,4 Trends in Parasitology, Month 2020, Vol. xx, No. xx
Box 1. A Multiagent Model of Neuropsychiatric Disease
Accumulating evidence suggests that the abnormal behaviour of T. gondii-infected intermediate/secondary hosts may
result from coinfection with other neurotropic pathogen(s). For example, serological testing of schizophrenic patients
and matched controls showed that schizophrenic patients more often had IgG antibodies to various coinfecting agents,
including T. gondii but also Chlamydia trachomatis, human herpesvirus-6, and measles virus [37,38]. In agreement with
these findings, our recent research has shown that UK foxes housed in sanctuaries with aberrant behaviours indicative
of neuropsychiatric impairment have a higher prevalence of T. gondii/vulpineCircovirus (FoxCV) coinfections relative to wild
foxes [64]. Thus, T. gondii infection and its interaction with other coinfecting neurotropic pathogens may be a factor
contributing to the aetiology of human neuropsychiatric disorders like schizophrenia.
An extension to this model could include additional interactions with host and pathogen genetics [22]. In terms of host
genetics, dysregulated expression or changes in the 'disrupted in schizophrenia ' (DISC1) protein have been associated
with a predisposition to schizophrenia [22]. Moreover, this protein has been implicated in the immune response against
T. gondii, with individuals with altered DISC1 having higher titres of T. gondii antibodies [65]. Furthermore, the HLA-D al-
leles (e.g., HLA-DQ3, HLA-DQA1/B1) have been shown to play a key role in determining the likelihood and outcome of
both T. gondii congenital disease and disease in immunocompromised patients [66]. These findings support a tripartite
model of clinical disease outcome, which could be further extended given the addition of strain-specific differences in par-
asite pathogenicity.
Parasite genotype may partly determine patterns of neuropsychiatric disease [63]. For example, mothers infected with
genotype I parasites have almost two times the odds of birthing a child who develops psychosis in later life, compared with
seronegative mothers [67]. This pattern is not seen for other genotypes, perhaps suggesting differing parasite tropisms
between lineages or differences in strain virulence factors, which could exacerbate the development of psychoses. Fur-
ther, so-called atypical genotypes (those not captured by the traditional type I–III classification) circulating in the
Americas have been associated with a greater burden and severity of ocular disease [63]. T. gondii epidemiology is therefore
multifactorial, with different factors interacting and combining to alter the likelihood and outcome of clinical – and plausibly
neuropsychiatric – disease. These factors likely include: (i) host genetics (and epigenetics); (ii) parasite genetics (types I–III,
atypical); (iii) population disease endemicity (seroprevalence); and (iv) coinfecting neurotropic agents.
Trends in Parasitologyinteractions between pathways [24]), act in parallel to explain the diversity of neuropsychiatric
disorders associated with T. gondii infection (Figure 2). Indeed, emerging evidence from rodent
models suggests that T. gondiimay even transgenerationally modulate host behaviour, including
anxious and depressive symptoms, via paternally inherited epigenetic changes [43].
Tip of the Iceberg: An Underestimated Burden of Disease?
Notwithstanding the general scarcity of data on the causal nature of T. gondii infection and human
neuropsychiatric disorders (with the exception of some cases of schizophrenia [13,22]), it is
possible to approximate the population attributable fraction (PAF) from the effect sizes
(odds ratios, ORs) estimated from meta-analyses (Box 2). This approach has been used to
estimate that 21.4% (13.7–30.6%) of schizophrenia cases are associated with T. gondii infection
[44]. Assuming a global incidence of schizophrenia of 15.2 per 100 000 [45], this means that
between 150 000 and 335 000 cases per year may be attributable to T. gondii. While this PAF
is based on an OR of 2.71 from an older systematic review [46,47] (higher than a more recent
review [19]; Figure 2), these numbers nonetheless highlight the potentially significant global
burden of T. gondii-associated schizophrenia. Indeed, this is particularly the case considering
that the psychopathology of T. gondii-related schizophrenia has been reported to bemore severe
and of longer duration than schizophrenia unrelated to T. gondii [48].
Another recent study estimated, assuming equivalence of ORs and risk ratios (RRs) (Box 2),
that T. gondii may account for approximately 17% of traffic accidents (6–29%) and 10% of
suicide attempts (3–19%) [23]. The World Health Organization (WHO) estimates that there are
20–50 million non-fatal traffic-related injuries per year [49]. Taking the central value of 35 million
accidents, T. gondii may therefore be associated with between 2.1 and 10.2 million non-fatal
traffic accidents per year. A similar illustrative calculation is possible for suicides and non-fatal
suicide attempts (NFSA). For every suicide fatality there are roughly 20 attempts [50] andTrends in Parasitology, Month 2020, Vol. xx, No. xx 5
Trends in Parasitologytherefore, given average annual global suicide rates of 9.94 per 100 000 [50], between
0.46 million and 2.91 million NFSAs per year may be attributable to infection with T. gondii.
How do these numbers compare with what is known about the overt burden of disease? It is
estimated that between 179 300 and 206 300 cases of congenital toxoplasmosis (CT) occur
annually [51], which result in an estimated 5900 cases of foetal loss and neonatal death,
24 700 cases of chorioretinitis in the first year of life, and 9300 cases of hydrocephalus
and other central nervous system (CNS) abnormalities [52]. Disease in immunocompromised
individuals also poses a considerable burden. For example, a recent meta-analysis estimated
that there are 13.1 million HIV patients coinfected with T. gondii [7]. While this figure is substantial,
current data nonetheless suggest that the now routine use of combination antiretroviral therapy
(cART) in individuals with HIV diagnoses has significantly mitigated the risk of T. gondii-associated
sequelae [including toxoplasmic encephalitis (TE)] [53]. Furthermore, acute outbreaks of ac-
quired toxoplasmosis, the largest of which resulted in 1400 human infections, occur locally and
sporadically [6]. The case numbers of the overt manifestations of T. gondii infection are therefore
likely dwarfed by those of neuropsychiatric disorders, non-fatal traffic accidents, suicide, and
NFSAs associated with latent T. gondii infection.
While a sizeable (yet inestimable) burden of sequelae may still be present amongst
immunocompromised/HIV-positive subpopulations either not seeking healthcare nor complyingBox 2. How Well Can the Odds Ratio Approximate the Risk Ratio?
Epidemiological studies are designed to determine whether there exists an association between an exposure (e.g., infection
with T. gondii) and an outcome (a particular neuropsychiatric disease). They can be broadly split into observational or
experimental study designs. Observational designs include case–control studies and cohort studies.
Case–control studies are particularly useful when an outcome is rare in a population. Case participants (with the disease)
and controls (without the disease) are included, and the exposure status of each participant is ascertained retrospectively.
The proportion of cases with the exposure of intertest is then compared with the corresponding proportion of controls,
usually expressed as an OR. A large majority of studies that have identified associations between neuropsychiatric
disorders and exposure to T. gondii have used case–control designs.
Cohort studies are an alternative to case–controls studies, with the key advantage that they measure exposure before the
outcome of interest, a more powerful indicator of causality. Cohort studies involve tracking groups of participants (cohorts),
either retrospectively or prospectively, with and without the exposure of interest and measuring the frequency (incidence)
of the disease in each group. The relative frequency of disease occurrence in exposed and nonexposed cohorts is typically
expressed as a risk ratio (RR).
The PAF can be calculated to determine what proportion of cases in a population can be attributed to the exposure of
interest and is given by:
PAF ¼ PE RR−1ð Þ
PE RR−1ð Þ þ 1 ½I
where PE is the proportion of the population exposed (e.g., to T. gondii). To calculate the PAF using the results from a
case–control study, one can either assume equivalence of the OR and RR, or adjust the OR using an estimate of the ab-
solute risk of the outcome in the unexposed population, RU [68],
RR ¼ OR
1−RUð Þ þ RU  OR ½II
If a disease is uncommon in the population, the denominator in Equation II tends to unity and gives equivalence of the RR
and the OR (the so-called rare disease assumption [69]). For diseases like schizophrenia, with a worldwide incidence of
15.2 per 100 000 [45], the OR will provide a good approximation of the RR. For more common outcomes, like addiction
disorder, with an incidence of approximately 2000 per 100 000 [19,70], an OR >1 will provide a biased overestimate of the
RR and can be adjusted using Equation II [68] (Figure I).
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Figure I. The Odds Ratio (OR) as an Approximation of the Risk Ratio (RR). Simulated cohorts were constructed
to illustrate the relationship between the incidence of an outcome, the OR and the RR. Each line indicates the change in OR
with increasing incidence and a fixed RR. Data on the incidence of outcomes and their OR associations with Toxoplasma
gondiiwere extracted from the literature: addiction disorders (using incidence data for all substance-use disorders) [19,70],
schizophrenia [45,47], suicide attempts [23,50], and traffic accidents (using incidence data for all transport-related injuries)
[70]. Adapted from [68].
Trends in Parasitologywith cART or TE prophylaxis [54], it remains plausible that, without accounting for the burden of
T. gondii-associated neuropsychiatric and behavioural conditions, we may be seeing only the tip
of the iceberg of T. gondii’s effects on human populations.
Implications and Applications for Public Health
While accurate estimates of the burden of latent T. gondii infection are required, so too are parallel
efforts towards improving public health interventions. Current interventions against T. gondii
primarily focus on prevention of congenital transmission and treatment of acute disease.
Prevention is largely limited to health advice on avoiding exposure during pregnancy and, in
some countries, antenatal screening programmes that offer treatment with spiramycin to
women who seroconvert during pregnancy. Treatment of acute disease is with pyrimethamine
and sulfadiazine, although treatment failures are significant [55].
Whether current treatment and prevention practices have any tangible effect on neuropsychiatric
sequelae will crucially depend on how the age of infection influences the likelihood of developing
neuropsychiatric disease. For example, if congenital acquisition of infection was particularly likelyTrends in Parasitology, Month 2020, Vol. xx, No. xx 7
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may be an effective intervention strategy.
By contrast, if the development of neuropsychiatric sequelae was mostly associated with
(horizontally) acquired infections, treatment of acute cases may be ineffectual since the vast
majority of such cases are unidentified because of mild and vague symptomology. While different
strategies [11] could be employed to reduce the burden of horizontally acquired infections, a
tailored response – one that efficiently distributes control resources – would require setting-
specific information on the predominant route of infection (bradyzoite vs oocyst). Such informa-
tion could be estimated using recent developments in sporozoite-specific serology [56].
Future Directions
Ultimately, to achieve better control of T. gondii and reduce its public health burden, it will be
important to further basic science research (including behavioural studies on non-human
primates with more similar neurological structures to humans) to better understand the mecha-
nisms driving neuropsychiatric associations, the role of host and parasite genetics on sequelae
(Box 1), and to conduct more powerful epidemiological research to strengthen the evidence
base for these associations (Box 2).
As the majority of epidemiological studies to date have been either cross-sectional or case–
control, they cannot determine the temporality of an association (Box 2). Cohort studies, by
contrast, can provide supportive evidence of causation by identifying the presence of exposure
(infection) prior to the onset of the outcome (neuropsychiatric disease). Ideally, this is achieved
by following individuals for many yearsmeasuring exposure and outcome through time. However,
in the case of schizophrenia, as the average age of onset is 23 years [16], such a long time to
disease onset realistically precludes the use of prospective cohorts. This limitation could be
ameliorated through the improvement of assays which provide estimates of the timing of infection
by measuring T. gondii-specific antibodies, for example, by improving the temporal resolution
obtained from IgG avidity tests. Nevertheless, in the absence of such advances, retrospective
cohorts, which are less resource-intensive and costly designs, could potentially be constructed
to identify temporality of the exposure–outcome relationship.
Randomised controlled trials (RCTs) can test the efficacy of T. gondii treatment on the alleviation
of neurological symptoms, an approach that has been taken before [57,58]. At least five RCTs
have been performed in T. gondii-positive schizophrenic patients to assess the impact of adjunc-
tive antiparasitic drugs on schizophrenic symptoms [57,58], although none have documented
any impact on the severity of schizophrenic symptoms. This finding could be due to the choice
of adjunctive treatment: azithromycin, trimethoprim, artemisinin, artemether, and valproate have
no demonstrated in vivo efficacy against bradyzoites [57]. It is also possible that treatment did
not affect existing symptoms because behavioural changes resulting from cyst formation are
irreversible, even in instances when cysts degrade [59].
Recently, spiramycin combined with metronidazole (a blood–brain barrier efflux pump inhibitor)
has been shown to significantly reduce bradyzoite cysts in latently infected mice [60] (several
other candidates, including miltefosine and guanabenz, have also shown promise; for a review
of antibradyzoite drug targets see [61]). This combination may therefore overcome drug brain
penetration issues, allowing antiparasitics to reach therapeutic concentrations. Nonetheless, if
behavioural abnormalities are indeed irreversible [59], future efforts should instead focus on pre-
ventative measures such as cat, human, and livestock vaccines. While an effective vaccine for
preventing T. gondii-induced sheep and goat abortions exists, the development of cat vaccines8 Trends in Parasitology, Month 2020, Vol. xx, No. xx
Outstanding Questions
What are the mechanisms underlying
epidemiological associations between
latent T. gondii infection and specific
neuropsychiatric disorders?
Towhat extent does parasite genotype
influence the onset, maintenance, and
type of neuropsychiatric disease?
How does age of infection influence the
likelihood of developing neuropsychiatric
disease?
Do interactions between T. gondii and
other neurotropic agents affect the
likelihood of developing neuropsychiatric
disease?
How effective are antiparasitic drugs at
reducing the symptoms of psychiatric
illness?
Trends in Parasitologyis in its infancy, and no human vaccine exists [though promising targets include, amongst others,
rhoptry proteins and surface antigen (SAG) proteins] [62].
Ensuring representation of different geographic regions in which epidemiological studies are
conducted – particularly where high-quality data remain scare, such as in South America and
sub-Saharan Africa (Figure 1B) – will also be important for several reasons. Firstly, parasite
genotype appears to be geographically heterogeneous and may possibly be predicted to drive
differences in the likelihood and severity of various clinical disease outcomes (Box 1) [63].
Secondly, host genetics and gene–environment interactions (including epigenetics [43]) may also
play a role in determining disease burden (Box 1). Finally, criteria for diagnosis of different neuropsy-
chiatric disorders are likely highly geographically variable, making outcome ascertainment differ by
global region. Therefore, to verify the robustness of these associations, it is imperative that new
epidemiological studies be performed in currently under-represented populations.
Concluding Remarks
The burgeoning number of associations of T. gondii with various neuropsychiatric disorders –
alongside compelling causal explanations supporting such links – suggest that the impact
of this pervasive parasite on global populations has been greatly underestimated. More re-
search is needed to strengthen the epidemiological evidence base for these associations,
but crucially also to improve understanding of the causative mechanisms (see Outstanding
Questions). Ultimately, better prevention, treatment, and transmission control will be required
to reduce the public health burden of T. gondii. There currently exists no effective treatment
for latent T. gondii infection; acute disease treatments, and prophylaxis to prevent vertical
transmission, are imperfect and there are no human or cat vaccines. Together with its com-
plex epidemiology, T. gondii is a substantial and incompletely understood global public
health challenge.
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